Novartis Pharma AG
Lichtstrasse 35
Basel
CH-4002
United States
Tel: 41-61-324-111
Fax: 41-61-324-8001
Website: http://www.novartis.com/
105 articles about Novartis Pharma AG
-
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
1/3/2024
Legend Biotech Corporation closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell cell therapies targeting Delta-like ligand protein 3, including Legend Biotech’s existing autologous CAR-T cell therapy candidate, LB2102.1 Under the terms of the license agreement closed , Legend Biotech will receive a $100 million upfront cash payment.
-
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
1/2/2024
Voyager Therapeutics, Inc. today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).
-
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
11/13/2023
Legend Biotech Corporation announced today that Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement (License Agreement) with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 (NCT05680922).
-
Pharming announces sale of priority review voucher
6/1/2023
Pharming Group N.V. announces that it has entered into a definitive agreement with Novartis Pharma A.G. to sell its Rare Pediatric Disease Priority Review Voucher to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.
-
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
3/6/2023
Voyager Therapeutics, Inc. today announced that Novartis AG (NYSE: NVS) has exercised its options to license novel capsids generated from Voyager’s TRACER™ capsid discovery platform for use in gene therapy programs against two undisclosed neurologic disease targets.
-
BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
12/20/2021
BeiGene, Ltd. today announced an option, collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan.
-
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
2/26/2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the closing of the collaboration and license agreement with Novartis Pharma AG, previously announced on January 11, 2021, to develop, manufacture, and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada
-
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
1/11/2021
Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries BeiGene to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales BeiGene has the option to co-detail tislelizumab in North America Both parties have freedom to conduct combination trials globally CAMBRID
-
Tilak Healthcare Inks New Partnership Agreement in Ophthalmology With Novartis to Expand Internationally
12/8/2020
Tilak Healthcare, a digital therapeutics pioneer specializing in the development of mobile medical application games used as monitoring and rehabilitation tools for chronic diseases, is proud to announce a framework agreement with Novartis Pharma AG for the promotion internationally of Tilak Healthcare’s first clinically validated mobile app for patient remo
-
Siemens Healthineers Announces Collaboration Agreement for Assay Development With an Initial Focus on Multiple Sclerosis
9/21/2020
Siemens Healthineers and Novartis collaboration to develop assays supporting Novartis’ therapeutic pipeline. Initial program to focus on development of serum neurofilament light chain (NfL) immunoassay for patients with Multiple Sclerosis (MS) and other neurological diseases. Global distribution on Siemens Healthineers immunoassay platforms.
-
MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
10/29/2019
MorphoSys AG announced the end of the clinical development program of MOR106 in atopic dermatitis.
-
MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients
4/23/2019
MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
-
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
4/23/2019
Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
-
Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals
4/22/2019
Rapha Capital Management, LLC, an investment management firm located in Miami, Florida, and their associated entities announced their participation in a Series C financing for Poseida Therapeutics.
-
Elbit Imaging Ltd. Announces Its Indirect Associate, Gamida Cell, Has Entered Into Agreement With Novartis Pharma AG
10/12/2015
-
Novartis Pharma AG Unloads Certain Specialty Product Rights to Merus for $29.5 Million
5/22/2015
-
Ophthotech Corporation Achieves Second $50 Million Enrollment Milestone Under Ex-US Licensing And Commercial Agreement With Novartis Pharma AG For Fovista
3/10/2015
-
Proteus Digital Health, Inc. Grows Leadership Team And Board Of Directors With Former Executives From Novartis Pharma AG, Novartis Pharma AG And Egreetings Network
4/16/2014
-
Unigene Laboratories, Inc. Announces Novartis Pharma AG' Disclosure of First Interpretable Results from Phase 3 Trial of Calcitonin (SMC021) in the Treatment of Post-menopausal Osteoporosis
11/14/2011
-
Novartis Pharma AG Selects Veeva Systems, Inc. CRM for Global Deployments
10/19/2010